Provided by Tiger Trade Technology Pte. Ltd.

Coherus BioSciences

2.06
-0.0800-3.74%
Post-market: 2.070.0100+0.49%19:45 EST
Volume:1.48M
Turnover:2.98M
Market Cap:248.99M
PE:1.54
High:2.16
Open:2.13
Low:1.95
Close:2.14
52wk High:2.62
52wk Low:0.7100
Shares:120.87M
Float Shares:111.19M
Volume Ratio:0.76
T/O Rate:1.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.34
EPS(LYR):0.2489
ROE:331.11%
ROA:-10.26%
PB:2.84
PE(LYR):8.28

Loading ...

BRIEF-Coherus Oncology Inc - Announces Agreement With Janssen - SEC Filing

Reuters
·
Feb 04

Coherus Oncology Inc: Janssen Will Provide Pasritamig to Company, Who Will Be Sponsor of Phase 1B Clinical Trial

THOMSON REUTERS
·
Feb 04

Coherus Oncology Inc - Janssen and Co Each Retain All Commercial Rights to Their Respective Compounds

THOMSON REUTERS
·
Feb 04

Coherus Oncology startet klinische Zusammenarbeit mit Janssen zur Erforschung von mCRPC-Therapie

Reuters
·
Feb 04

Coherus Oncology (CHRS) Taps ATM Facility: Strategic Lifeline or Dilution Trade-Off for Its Pipeline?

Simply Wall St.
·
Jan 26

Oppenheimer Initiates Coverage on Coherus BioSciences With Outperform Rating

MT Newswires Live
·
Jan 23

Coherus Oncology Inc - Loqtorzi Projected to Reach $150-200M in Revenues by 2028 - SEC Filing

THOMSON REUTERS
·
Jan 13

January 2026 Penny Stock Spotlight: Three Promising Picks

Simply Wall St.
·
Jan 12

Spyglass Pharma Appoints Jean-FrÉDÉRic Viret as Chief Financial Officer

THOMSON REUTERS
·
Jan 06

Coherus Oncology Announces Positive Preclinical and Early Clinical Results for Investigational CCR8 Antibody Tagmokitug

Reuters
·
Jan 05

Coherus Oncology Reports LOQTORZI Plus Chemotherapy Nearly Doubles Survival in Nasopharyngeal Carcinoma

Reuters
·
Dec 08, 2025

Coherus Oncology - Loqtorzi Shows 31-Month Improvement and 38% Reduction in Death Risk

THOMSON REUTERS
·
Dec 08, 2025

Coherus Announces Six-Year Jupiter-02 Follow-up Results Showing Loqtorzi® Plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

THOMSON REUTERS
·
Dec 08, 2025

Coherus Oncology Q3 Sales USD 11.571 Million Vs. IBES Estimate USD 13.4 Million

Reuters
·
Nov 20, 2025

H.C. Wainwright Remains a Buy on Coherus Biosciences (CHRS)

TIPRANKS
·
Nov 15, 2025

Coherus Oncology files $150M mixed securities shelf

TIPRANKS
·
Nov 14, 2025

BRIEF-Coherus Oncology Files For Mixed Shelf Offering Of Up To $150 Million- SEC Filing

Reuters
·
Nov 14, 2025

Coherus Oncology Inc : Files for Mixed Shelf Offering of up to $150 Mln- SEC Filing

THOMSON REUTERS
·
Nov 14, 2025

Coherus Oncology Reports Promising Phase 1b Results for CHS-114 in Head and Neck Cancer

Reuters
·
Nov 07, 2025

Coherus Oncology Q3 sales miss estimates, LOQTORZI revenue up 12%

Reuters
·
Nov 07, 2025